CNSP Quote, Financials, Valuation and Earnings

Ligand Pharmaceuticals has a net margin of -- compared to CNS Pharmaceuticals's net margin of -13.84%. CNS Pharmaceuticals's return on equity of -- beat Ligand Pharmaceuticals's return on equity of 5.97%.

CNS Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 350.45%. On the other hand Ligand Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 25.68%. Given that CNS Pharmaceuticals has higher upside potential than Ligand Pharmaceuticals, analysts believe CNS Pharmaceuticals is more attractive than Ligand Pharmaceuticals.

CNS Pharmaceuticals has a beta of 1.067, which suggesting that the stock is 6.725% more volatile than S&P 500. In comparison Ligand Pharmaceuticals has a beta of 1.038, suggesting its more volatile than the S&P 500 by 3.81%.

CNS Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals pays -- of its earnings as a dividend. Ligand Pharmaceuticals pays out -- of its earnings as a dividend.

CNS Pharmaceuticals quarterly revenues are --, which are smaller than Ligand Pharmaceuticals quarterly revenues of $51.8M. CNS Pharmaceuticals's net income of -$5.6M is higher than Ligand Pharmaceuticals's net income of -$7.2M. Notably, CNS Pharmaceuticals's price-to-earnings ratio is -- while Ligand Pharmaceuticals's PE ratio is 45.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals is -- versus 13.58x for Ligand Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to CNS Pharmaceuticals's net margin of -49.65%. CNS Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

CNS Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 350.45%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than CNS Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than CNS Pharmaceuticals.

CNS Pharmaceuticals has a beta of 1.067, which suggesting that the stock is 6.725% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

CNS Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

CNS Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. CNS Pharmaceuticals's net income of -$5.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, CNS Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -- compared to CNS Pharmaceuticals's net margin of -63.65%. CNS Pharmaceuticals's return on equity of -- beat Revance Therapeutics's return on equity of --.

CNS Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 350.45%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 147.96%. Given that CNS Pharmaceuticals has higher upside potential than Revance Therapeutics, analysts believe CNS Pharmaceuticals is more attractive than Revance Therapeutics.

CNS Pharmaceuticals has a beta of 1.067, which suggesting that the stock is 6.725% more volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

CNS Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

CNS Pharmaceuticals quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. CNS Pharmaceuticals's net income of -$5.6M is higher than Revance Therapeutics's net income of -$38.1M. Notably, CNS Pharmaceuticals's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals is -- versus 1.16x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks has a net margin of -- compared to CNS Pharmaceuticals's net margin of -186.56%. CNS Pharmaceuticals's return on equity of -- beat Zymeworks's return on equity of -27.06%.

CNS Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 350.45%. On the other hand Zymeworks has an analysts' consensus of $19.86 which suggests that it could grow by 40.42%. Given that CNS Pharmaceuticals has higher upside potential than Zymeworks, analysts believe CNS Pharmaceuticals is more attractive than Zymeworks.

CNS Pharmaceuticals has a beta of 1.067, which suggesting that the stock is 6.725% more volatile than S&P 500. In comparison Zymeworks has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.109%.

CNS Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals pays -- of its earnings as a dividend. Zymeworks pays out -- of its earnings as a dividend.

CNS Pharmaceuticals quarterly revenues are --, which are smaller than Zymeworks quarterly revenues of $16M. CNS Pharmaceuticals's net income of -$5.6M is higher than Zymeworks's net income of -$29.9M. Notably, CNS Pharmaceuticals's price-to-earnings ratio is -- while Zymeworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals is -- versus 17.03x for Zymeworks. Usually stocks with elevated PS ratios are considered overvalued.